Puretech founded entity vedanta biosciences announces phase 2 study of ve202 in ulcerative colitis did not meet primary endpoint

Boston--(business wire)--puretech founded entity vedanta biosciences announces phase 2 study of ve202 in ulcerative colitis did not meet primary endpoint.

PRTC Ratings Summary

PRTC Quant Ranking